



# Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities

Fan Chen<sup>1</sup>, Xinghui He<sup>2</sup>, Guoming Luan<sup>2</sup> and Tianfu Li<sup>1\*</sup>

<sup>1</sup> Beijing Key Laboratory of Epilepsy Research, Department of Neurology, Beijing Institute for Brain Disorders, Sanbo Brain Hospital, Capital Medical University, Beijing, China, <sup>2</sup> Beijing Key Laboratory of Epilepsy Research, Department of Neurosurgery, Beijing Institute for Brain Disorders, Sanbo Brain Hospital, Capital Medical University, Beijing, China

## OPEN ACCESS

### Edited by:

Fernando Cendes,  
Universidade Estadual de Campinas,  
Brazil

### Reviewed by:

Cherubino Di Lorenzo,  
Fondazione Don Carlo Gnocchi Onlus  
(IRCCS), Italy  
Kette D. Valente,  
University of São Paulo, Brazil

### \*Correspondence:

Tianfu Li  
tianfull66@126.com

### Specialty section:

This article was submitted to  
Epilepsy,  
a section of the journal  
Frontiers in Neurology

Received: 05 October 2018

Accepted: 29 January 2019

Published: 26 February 2019

### Citation:

Chen F, He X, Luan G and Li T (2019)  
Role of DNA Methylation and  
Adenosine in Ketogenic Diet for  
Pharmacoresistant Epilepsy: Focus on  
Epileptogenesis and Associated  
Comorbidities. *Front. Neurol.* 10:119.  
doi: 10.3389/fneur.2019.00119

Epilepsy is a neurological disorder characterized by a long term propensity to produce unprovoked seizures and by the associated comorbidities including neurological, cognitive, psychiatric, and impairment the quality of life. Despite the clinic availability of several novel antiepileptic drugs (AEDs) with different mechanisms of action, more than one-third of patients with epilepsy suffer with pharmacoresistant epilepsy. Until now, no AEDs have been proven to confer the efficacy in alteration of disease progression or inhibition of the development of epilepsy. The ketogenic diet, the high-fat, low-carbohydrate composition is an alternative metabolic therapy for epilepsy, especially for children with drug-resistant epilepsy. Recently clinical and experimental results demonstrate its efficacy in ameliorating both seizures and comorbidities associated with epilepsy, such as cognitive/psychiatric concerns for the patients with refractory epilepsy. Of importance, ketogenic diet demonstrates to be a promising disease-modifying or partial antiepileptogenesis therapy for epilepsy. The mechanisms of action of ketogenic diet in epilepsy have been revealed recently, such as epigenetic mechanism for increase the adenosine level in the brain and inhibition of DNA methylation. In the present review, we will focus on the mechanisms of ketogenic diet therapies underlying adenosine system in the prevention of epileptogenesis and disease modification. In addition, we will review the role of ketogenic diet therapy in comorbidities associated epilepsy and the underlying mechanisms of adenosine.

**Keywords:** ketogenic diet, epilepsy, epileptogenesis, comorbidities, adenosine

## INTRODUCTION

Possible implications of the ketogenic diet (KD), a high-fat, low-carbohydrate diet, have been demonstrated in neurological fields, for instance: cognitive decline and dementia (1, 2), Parkinson disease (3), multiple sclerosis and its cognitive complications (4, 5), migraine and cluster headache (6–8). Epilepsy is a chronic neurological disorder characterized by a long term propensity to produce unprovoked seizures and by the associated comorbidities including neurological, cognitive, psychiatric, and impairment the quality of life. (9). Despite several novel antiepileptic

drugs (AEDs) move into clinic in recent years, pharmacotherapy is not effective in 30% of all cases, and up to 30 percent of patients with epilepsy remains refractory or drug resistant (10, 11), most of them are not suitable for resective operation and have to continue to suffer from uncontrolled recurrent seizures and the lower quality of life involved an extensive range of cognitive and psychiatric symptoms. However, current AEDs have been developed for antiictogenesis (inhibition of seizures) and not for antiepileptogenesis (prevention of epilepsy or disease-modification) (12). In addition, epilepsy has been regarded as prototype neuropsychiatric illness with interface of neurology and psychiatry, and treatment of comorbidity may autonomously ameliorate the efficacy for seizures inhibition and enhance the quality of life for patients with epilepsy (13, 14). KD was developed as a non-pharmacological treatment for epilepsy, and was regarded as a last resort of therapy for children with pharmacoresistant epilepsy. The efficacy of KD in the treatment of pharmacoresistant epilepsy suggests that the mechanisms of action in controlling seizures conferred by KD are different with that of conventional AEDs (15). Clinical and experimental results indicated that KD therapy is a promising disease-modifying or partial antiepileptogenesis treatment for pharmacoresistant epilepsy (16, 17). In addition, KD therapy provides effectiveness in ameliorating both seizures and comorbidities associated with epilepsy, such as cognitive/psychiatric concerns for the patients with pharmacoresistant epilepsy (18–21), and improving the quality of life (22, 23). The satisfactory efficacy in the treatment of patients with pharmacoresistant may offer the impetus to uncover novel mechanisms underlying the development of epilepsy and associated comorbidities. Therefore, in order to develop novel therapies aim to modify the development of epilepsy (disease modification) and associated comorbidities, there is a critical need to strengthen the extensive research for KD from bench to bedside and bedside to bench. The present review is indicted not to offer a comprehensive overview of all potential mechanisms, but to focus on the role of KD therapy in epileptogenesis, comorbidities associated with epilepsy, as well as the possible mechanisms underlying adenosine dysfunction.

## PREVENTION OR MODIFICATION OF EPILEPTOGENESIS OF THE KD THERAPY

The term epileptogenesis refers to a complex processes that happens prior to the initial epileptic seizure appears to translate the epileptic brain with higher propensity of recurrent seizures and processes that aggravate seizures to drug resistant (12), which involves alterations in expression and functions of receptors and ion channels, epigenetic alterations, inflammatory mechanisms, glial activation, and reorganization of neuronal circuitry (16, 24). The true antiepileptogenic efficacy means prophylactic drug treatment in prevention of spontaneous recurrent seizures after a brain insult. The term disease modification refers to the therapy may modulate the intrinsic process of the disease even though it may not hamper the occurrence of a disease (12). The halt of development of epilepsy after initial diagnosis is defined as a therapy of disease modification (12). Until now, conventional

AEDs offered efficacy only for inhibition of epileptic seizures and not for prophylaxis therapeutic intervention of epilepsy or modulation of the epilepsy development. Therefore, novel avenues for ideal therapies to hamper disease development of epilepsy are imperative (16).

The high-fat, low-carbohydrate KD has been regarded as a palliative therapy for pharmacoresistant epilepsy in children and adults. The 30% of children with pharmacoresistant epilepsy on the diet had more than 90% seizure reduction, and 52% of the children had more than 50% seizure reduction at 3 months (25). Even in adult patients with drug resistant epilepsy, 32% of those using KD attained the efficacy of seizure reduction more than 50% (26). Previous data on KD therapy in adolescents and adults indicted that up to 13% of patients with pharmacoresistant epilepsy were seizure-free and approximately two thirds of patients reduced seizure more than 50% (27). Currently, most of the KD therapy studies in epilepsy mainly focused on KD efficacy in seizure control, and no valid and well-designed clinical research to evaluate the efficacy of KD therapy on antiepileptogenesis or disease modification has been implemented (16). The emerging clinical findings indicated that KD can also provide antiepileptogenic and disease-modifying therapies in pharmacoresistant epilepsy (17, 28). Some patients with KD therapy become long term seizure-free even after termination of KD therapy (17). The long term clinical efficacy in KD therapy for epilepsy over time might suggest the mechanism underlying disease-modification (29).

In addition, experimental research also indicated that KD therapy prevented disease progression in two different typical animal models of epilepsy induced by electrical kindling and chemoconvulsants (16). In the pentylenetetrazole kindling mice model with consecutive injection of subconvulsant doses of pentylenetetrazole, KD but not a typical AEDs affords long-lasting protective efficacy (increased seizures threshold) against epileptic seizures caused by pentylenetetrazole even after termination of KD. This kindling model is an ideal animal model of epileptogenesis and has been extensively evaluated to study the pathomechanisms underlying the epileptogenic process (16). Therefore, the lasting outcomes in this kindling paradigms extensively used to evaluate the efficacy of the inherent capacity of antiepileptogenic therapy are likely to consistent with an antiepileptogenic or disease modification effect (16, 29, 30). In rats post-status epilepticus model of temporal lobe epilepsy evoked by pilocarpine, animals on the control diet displayed seizures progressed in severity and frequency, while animals on the KD diet displayed the epileptic seizures with severity and frequency significantly decreased (16). Of importance, reduction of seizures in the model maintained even after the diet reversal. Post-status epilepticus model of temporal lobe epilepsy have been extensively implanted to explore the novel AEDs with potential disease modifications, which is characterized by an first brain lesion, a dormant period, reactive astrogliosis in hippocampus and alteration of brain networks resulting in recurrent spontaneous seizures (12, 31). The results in the study highly indicated the KD offered a role in disease modification or partial antiepileptogenesis in a typical model of temporal lobe epilepsy (16).

Recent evidence demonstrated that KD treatment also confers antiepileptogenesis efficacy in genetic models of epilepsy with *Kcna1*-null mutant mice (32, 33). *Kcna1*-null mutant mice model occupied with several characteristics, such as early onset epilepsy with a severe seizure phenotype with myoclonic and generalized tonic-clonic seizures, resistant to traditional AEDs, cognitively impaired, cardiac arrhythmias and sudden death (33). It is an ideal model to study the epileptogenesis or disease modification, because the mice in the model experienced several kinds of temporal lobe epilepsy syndromes, and gradually progressed into terminal events associated with human sudden unexpected death in epilepsy (33–38). KD therapy demonstrated to retard the disease development, postpone the advent of catastrophic seizures, and to increase the life span by 47% in this model of progressive epilepsy (33).

However, there exist controversies on whether KD therapy has the role of antiepileptogenesis or disease modification. In the post-traumatic epilepsy model, a good model to test antiepileptogenic therapies (39), no evidence for KD-induced antiepileptogenesis was demonstrated (40). In rats post-status epilepticus model of temporal lobe epilepsy induced by pilocarpine, another commonly used model to verify disease modification or epileptogenesis (12), KD therapy did not demonstrated to halt the clinical course of epilepsy development after status epilepticus induced by an initial lithium-pilocarpine administration (41).

In addition, the adverse effects of the KD had been reported in extensive studies (42). The chief adverse effects were gastrointestinal symptoms, such as diarrhea, obstipation, vomiting (43–46) and weight down (43, 46). Other adverse effects were also addressed, such as abdominal pain, renal stones, gallstones, infectious disease (pneumonia and sepsis), acute pancreatitis, hypercholesterolaemia, dropped bone matrix density, fatty liver, tachycardia, nephrocalcinosis, status epilepticus, acidosis, dehydration, prolonged of hospitalization, hunger and any infection of the respiratory tract (42).

## ADENOSINE-DEPENDENT EPIGENETIC MECHANISM INVOLVING THE DISEASE MODIFICATION THERAPY OF KD

Extensive experimental and clinical evidence demonstrated that disruption of glia-derived adenosine system as one of the important mechanism subserved the development of epilepsy (47), and therapeutic adenosine augmentation exerts anticonvulsant and seizure terminating efficacy (15, 47–53), mediated by both receptor-dependent and receptor-independent pathways (54). Antiepileptogenic effects (anticonvulsant effects) of adenosine are through adenosine receptor-dependent pathway, mainly acting via adenosine A1 receptors (A1R) (15, 48, 50, 52, 55–57). Acting through presynaptic A1R, adenosine may regulate multiple neurotransmitters releasing, and the most important inhibitory actions base on the glutamatergic system in the central nervous system (15, 58). On the other hand, acting through post-synaptic A1R, adenosine has been proved to hyperpolarize the synaptic potentials in post-synaptic neurons and boost

NMDA receptor inhibition via activation of K<sup>+</sup> channels (59). Our previous study demonstrated that KD increased the level of adenosine in the brain and exerted anticonvulsant effects via A1R (15).

Apart from its receptor-dependent efficacy, adenosine has been indicated to play a crucial role in modulation of DNA methylation homeostasis in receptor-independent effects (51, 54, 60). Adenosine is regarded as a mandatory end product of S-adenosylmethionine dependent transmethylation reactions (60–62). Upregulated adenosine kinase expression or deficiency of adenosine drives an increase in the transmethylation pathway leading to hypermethylated DNA, which is potentially implicated in epileptogenesis. Deficiency of adenosine and DNA hypermethylation develop into a vicious circle associated with in the onset of epileptogenesis, spontaneous seizures, progression of epilepsy and chronic pharmacoresistant epilepsy (60). Therefore, to restore the adenosine level or DNA methylation in epilepsy might be the novel and promising therapeutic target (62). Studies have demonstrated that focal augmentation of adenosine remarkably down-regulate DNA methylation in post-status epilepticus model of temporal lobe epilepsy (16). Therefore, adenosine and DNA methylation might be highlighted as emerging antiepileptogenic or disease-modification agents for epilepsy therapy (32, 62, 63).

DNA methylation has been proved to exert high fidelity modulation of gene expression in brain and play an important role in the pathogenic mechanisms of onset of epileptogenesis and development of epilepsy. Therefore, intervention of DNA methylation is regarded as a reasonable prophylaxis therapy for epilepsy in view of the fact that it acts on directly the predominant pathway that initiates the multiple downstream cellular and molecular events mediating epileptogenesis (62). Global DNA hypermethylation has been demonstrated in patients with temporal lobe epilepsy and rats post-status epilepticus model of temporal lobe epilepsy (16, 51, 61, 62). Adenosine exerts a crucial role as an endogenous regulator of DNA methyltransferases activity. In recent study, KD therapy has been indicated to prevent disease progression via increased adenosine and decreased DNA methylation. Of note, down-regulation of DNA methylation by KD therapy maintained after diet discontinuation (16). Based on this premise, it is likely that the KD treatment plays its antiepileptogenic efficacy via an adenosine-dependent DNA methylation modulation (32).

## COMORBIDITIES ASSOCIATED WITH EPILEPSY

The term comorbidities have been defined as “any additional distinct clinical entity” (64, 65). Several different kinds of comorbidities, such as cognitive comorbidities, psychiatric comorbidities and neurological comorbidities, exist in epilepsy (66). Psychiatric and neurological comorbidities are relatively frequent in epilepsy (67), affecting on average, 30–50% of patients (68). Currently, the goals of therapy for patients with epilepsy are not limited to reach the aim of seizure free, but must also the improvement of comorbidities associated with epilepsy,

including neurological, psychiatric and cognitive comorbidities. Cognitive comorbidities include memory, attention, executive dysfunction, etc. Learning is one cognitive issue or a consequence and learning problems that lead to an major obstacle to get educational and professional success (66); Psychiatric comorbidities refer to behavior and mood problems, such as bipolar disorder, attention deficit hyperactivity disorder (ADHD), depression, anxiety disorders and autism (66). Neurological comorbidities are migraine headache (69), sleep disorders, such as sleep apnea, insomnia, restless legs syndrome, and the parasomnias (70), pain (neuropathic pain, fibromyalgia, chronic pain) and other (asthma, diabetes, and high blood pressure) (71). The comorbidities are frequent seen in patients with epilepsy, and can deteriorate quality of life further than seizures themselves do (18). Currently, the bidirectional relation between epilepsy and associated comorbidities has been paid much more attentions (72–76). Research upon the overlap of psychiatric and neurologic symptoms from a pathophysiologic and phenomenologic perspective is becoming a hot topic in epilepsy. The comorbidities associated with epilepsy are attributable to recurrent seizures and medications. In fact, the utmost recent data demonstrate that some neurocognitive and psychological comorbidities as well as structural brain changes predate the onset of seizures, with the early cognitive compromise being further magnified by the onset of epileptogenesis, and later on, by the chronicity of seizures (77–79). Therefore, the comorbidities need to be addressed in an early stage of the illness as they have a profound worse influence on the quality of life and complicate the therapeutic management of epilepsy (66). Base on this premise, it is crucial that therapy for epilepsy should aim at both seizures and comorbidities associated with epilepsy, because improving the lives of persons with epilepsy rely more on addressing comorbidities than seizures themselves (80, 81).

Even though the KD therapy has been proved to be efficacy in inhibition of seizures in patients with pharmacoresistant epilepsy, much more attention is needed to comorbidities and clinical advantages of KD. Recent study demonstrated that KD therapy afford a beneficial contribution on behavioral and cognitive function in children and adolescents with pharmacoresistant epilepsy (18, 82, 83). On the other hand, studies with objective neuropsychiatric tests demonstrated that KD therapy afford benefits on alertness without amelioration in global cognition (20). KD therapy provided cognitive improvements in patients with pharmacoresistant epilepsy, although it is unclear if this is an independent efficacy of the diet (84). More specifically, an improvement is observed in mood, sustained attention, and social interaction. This activation of mood and cognition was not associated with the decrease of seizure frequency and correlates with the prominent efficacy of the KD (19, 19, 20, 84), and appeared no relation to AEDs diminution, age when KD therapy is initiated, type of KD, and sleep amelioration (19, 20). In consistent with the effects of KD to control seizure and improve cognition in patients with pharmacoresistant epilepsy, several lines of experimental research also demonstrated the neuroprotective efficacy on cognition (21, 85, 86). For the status of KD therapy in psychiatric comorbidities associated epilepsy, such as depression or bipolar

disorder, although currently there is no long-term, prospective, randomized, placebo-controlled crossover dietary clinical trial (87), KD has been regarded as a novel frontier therapy for mood disorder, particularly in therapy with drug resistant mood disorder (88).

KD therapy has a long been used in children with pharmacoresistant epilepsy. However, overall distinct role of KD in comorbidities associated with epilepsy, especially psychiatric comorbidities is unclear. The impact of KD in psychiatric disorders is speculative. There is no solid evidence to corroborate this statement. Currently, there is inadequate evidence for the administration of KD in psychiatric comorbidities associated with epilepsy including behavior and mood problems, such as attention deficit disorder, bipolar disorder, depression, anxiety disorders, schizophrenia, autism spectrum disorder, and combinations of these conditions (87). So far, KD therapy is still not a recommended treatment option for the psychiatric disorders.

## ADENOSINE DYSFUNCTION IN COMORBIDITIES ASSOCIATED WITH EPILEPSY

For the cognitive comorbidities, extensive clinical and experimental study has been proved that adenosine plays an important role in controlling inflammation inhibiting seizures (15, 47–50, 52, 53, 55, 56, 89), and regaining cognitive function when cognition is afflicted secondary to epilepsy (47, 52, 53, 60). Adenosine impacts cognition processes via action on adenosine receptor A2A (A2AR) signaling pathway and regulation of neurotransmitters including glutamatergic, dopaminergic, GABAergic, and BDNF (90). The astrocytic A2AR might play a prominent role in interacts with glutamate transporter-1 and thereby regulates astroglial glutamate uptake. Therefore, malfunction of A2AR in astrocytes, by modulating glutamate transporter-1 activity, initiates an astrocyte-to-neuron wave of communication causing disruption of glutamate system and cognitive impairment (91). Increasing the adenosine level in the brain via pharmacologic inhibition of the key enzyme of adenosine clearance, or intrastriatal implants of engineered adenosine-releasing cells can improve cognitive function (92). KD therapy has been proved to increase the adenosine level in the brain (15, 16), and KD therapy has been demonstrated to afford an improvement of cognitive activation in the patients with epilepsy (19). Based on the evidence above, it is strongly suggested that KD therapy ameliorated the cognition deficit though augmentation of the adenosine in the brain, which might be highly regarded as an ideal method for the therapy of cognitive comorbidities associated with epilepsy.

Depression is the common psychiatric comorbidities in patients with epilepsy (93). A1R signaling pathway in astrocytes has been demonstrated to be necessary in decreasing depressive-like behaviors secondary to sleep deprivation in mice (90), which indicated the activation of adenosine signaling triggered by sleep deprivation contributes to inhibition of depression (94). S-adenosylhomocysteine, a precursor of adenosine, has been found to be efficacy for the patients with treatment-resistant depressive

disorder (95). The common clinical antidepressive treatment, such as acupuncture (96, 97) and deep brain stimulation (98) has been indicated via increasing of adenosine and activation of A1R in the brain (99–101). KD therapy, the adenosine augmentation approach (15, 16), has been demonstrated to be effective in inhibition of depression (87). Therefore, it is suggested that one of the mechanisms underlying the KD therapy for depression via A1R. KD therapy might represent a novel strategy for the therapy of psychiatric comorbidities associated epilepsy.

Sleep disorders is the common neurologic comorbidities associated with epilepsy (70). Extensive studies have demonstrated that adenosine plays a crucial role in modulation of sleep homeostasis (90, 102, 103). Adenosine receptors A1R and A2AR have been demonstrated to play an important role in sleep modulation (90). A1R agonists promote sleep (104), while A1R antagonists inhibit sleep (105), via basal forebrain mediated mechanisms, respectively. A2AR agonist also has been demonstrated to promote sleep (106), via activation of cells of the leptomeninges or nucleus accumbens to reinforce the neuronal activity in ventrolateral preoptic region (107). This effect of sleep regulation was not found in A2AR-deficient mice (108). Inhibition of the A2AR in the shell of the nucleus accumbens (90, 109) has been reputed the potential mechanism of the arousal effects of caffeine (non-selective antagonist of A1R and A2AR).

It is well-accepted that of upregulation of adenosine (increasing adenosine level or activation of adenosine receptors) promote sleep and downregulation of adenosine (decrease

adenosine level or inactivation of adenosine receptors) induce wakefulness (90). It is hypothesized that a decreased adenosine tone uniformly forms the base for both epilepsy and sleep disruption (90). However, recent study found a lineal association of regionally distinguishable dichotomous levels of adenosine in one model represent both epilepsy and comorbid sleep disorders (110). In the model, adenosine level was decreased in the dorsal hippocampus contributing to seizure threshold diminution, while adenosine level was increased in the lateral hypothalamus leading to chronic partial sleep deprivation. To clarify the specific brain regional alterations in adenosine tone in patients underlies both epilepsy and sleep disorder is important for the targeted therapy in the future.

## AUTHOR CONTRIBUTIONS

The overall review design was conceived and supervised by TL. FC, XH, and GL helped in the writing different parts of the review. All authors read and approved the final manuscript.

## ACKNOWLEDGMENTS

This Project was supported by the Grant from the National Key Research and Development Program of China (NO. 2016YFC0904401), the Grant from the BIBD-PXM2013\_014226\_07\_000084, National Natural Science Foundation of China (81571275).

## REFERENCES

- Krikorian R, Shidler MD, Dangelo K, Couch SC, Benoit SC, Clegg DJ. Dietary ketosis enhances memory in mild cognitive impairment. *Neurobiol Aging* (2012) 33:419–25. doi: 10.1016/j.neurobiolaging.2010.10.006
- Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. *Nutr Metab*. (2009) 6:31. doi: 10.1186/1743-7075-6-31
- Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heysfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. *Neurology* (2005) 64:728–30. doi: 10.1212/01.WNL.0000152046.11390.45
- Storoni M, Plant GT. The therapeutic potential of the ketogenic diet in treating progressive multiple sclerosis. *Mult Scler Int*. (2015) 2015:681289. doi: 10.1155/2015/681289
- Francis HM, Stevenson RJ. Potential for diet to prevent and remediate cognitive deficits in neurological disorders. *Nutr Rev*. (2018) 76:204–17. doi: 10.1093/nutrit/nux073
- Di Lorenzo C, Curra A, Sirianni G, Coppola G, Bracaglia M, Cardillo A, et al. Diet transiently improves migraine in two twin sisters: possible role of ketogenesis? *Funct Neurol*. (2013) 28:305–8. doi: 10.11138/FNeur/2013.28.4.305
- Di Lorenzo C, Coppola G, Sirianni G, Di Lorenzo G, Bracaglia M, Di Lenola D, et al. Migraine improvement during short lasting ketogenesis: a proof-of-concept study. *Eur J Neurol*. (2015) 22:170–7. doi: 10.1111/ene.12550
- Di Lorenzo C, Coppola G, Di Lenola D, Evangelista M, Sirianni G, Rossi P, et al. Efficacy of modified Atkins ketogenic diet in chronic cluster headache: an open-label, single-arm, clinical trial. *Front Neurol*. (2018) 9:64. doi: 10.3389/fneur.2018.00064
- Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia* (2005) 46:470–2. doi: 10.1111/j.0013-9580.2005.66104.x
- Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. *JAMA Neurol*. (2018) 75:279–86. doi: 10.1001/jamaneurol.2017.3949
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. *N Engl J Med*. (2000) 342:314–9. doi: 10.1056/NEJM200002033420503
- Loscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. *Pharmacol Rev*. (2010) 62:668–700. doi: 10.1124/pr.110.003046
- Salpekar JA, Mishra G, Hauptman AJ. Key issues in addressing the comorbidity of depression and pediatric epilepsy. *Epilepsy Behav*. (2015) 46:12–8. doi: 10.1016/j.yebeh.2015.02.036
- Zhen XH, Quan YC, Jiang HY, Wen ZS, Qu YL, Guan LP. Fucosterol, a sterol extracted from *Sargassum fusiforme*, shows antidepressant and anticonvulsant effects. *Eur J Pharmacol*. (2015) 768:131–8. doi: 10.1016/j.ejphar.2015.10.041
- Masino SA, Li T, Theofilas P, Sandau US, Ruskin DN, Fredholm BB, et al. A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors. *J Clin Invest*. (2011) 121:2679–83. doi: 10.1172/JCI57813
- Lusardi TA, Akula KK, Coffman SQ, Ruskin DN, Masino SA, Boison D. Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. *Neuropharmacology* (2015) 99:500–9. doi: 10.1016/j.neuropharm.2015.08.007
- Caraballo R, Vaccarezza M, Cersosimo R, Rios V, Soraru A, Arroyo H, et al. Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients. *Seizure* (2011) 20:640–5. doi: 10.1016/j.seizure.2011.06.009

18. Nickels KC, Zaccariello MJ, Hamiwka LD, Wirrell EC. Cognitive and neurodevelopmental comorbidities in paediatric epilepsy. *Nat Rev Neurol*. (2016) 12:465–76. doi: 10.1038/nrneuro.2016.98
19. Ijff DM, Postular D, Lambrechts D, Majoie M, de Kinderen R, Hendriksen J, et al. Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial. *Epilepsy Behav*. (2016) 60:153–7. doi: 10.1016/j.yebeh.2016.04.033
20. van Berkel AA, Ijff DM, Verkuyl JM. Cognitive benefits of the ketogenic diet in patients with epilepsy: a systematic overview. *Epilepsy Behav*. (2018) 87:69–77. doi: 10.1016/j.yebeh.2018.06.004
21. Jiang Y, Lu Y, Jia M, Wang X, Zhang Z, Hou Q, et al. Ketogenic diet attenuates spatial and item memory impairment in pentylenetetrazol-kindled rats. *Brain Res*. (2016) 1646:451–8. doi: 10.1016/j.brainres.2016.06.029
22. Barwick K, Parker T, Murphy N, Todd A, Leveritt M, Wilkinson SA. Development and pilot testing of a parent-reported health-related quality of life measure for children on the ketogenic diet: The KetoQoL. *Nutr Diet*. (2017) 74:521–8. doi: 10.1111/1747-0080.12348
23. Bruce S, Devlin A, Air L, Cook L. Changes in quality of life as a result of ketogenic diet therapy: a new approach to assessment with the potential for positive therapeutic effects. *Epilepsy Behav*. (2017) 66:100–4. doi: 10.1016/j.yebeh.2016.10.001
24. Klein P, Dingleline R, Aronica E, Bernard C, Blumcke I, Boison D, et al. Commonalities in epileptogenic processes from different acute brain insults: do they translate? *Epilepsia* (2018) 59:37–66. doi: 10.1111/epi.13965
25. Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. *Epilepsia* (2013) 54:481–6. doi: 10.1111/epi.12069
26. Caraballo R, Darra F, Reyes G, Armeno M, Cresta A, Mestre G, et al. The ketogenic diet in patients with myoclonic status in non-progressive encephalopathy. *Seizure* (2017) 51:1–5. doi: 10.1016/j.seizure.2017.07.002
27. Felton EA, Cervenka MC. Dietary therapy is the best option for refractory nonsurgical epilepsy. *Epilepsia* (2015) 56:1325–9. doi: 10.1111/epi.13075
28. Dressler A, Stocklin B, Reithofer E, Benninger F, Freilinger M, Hauser E, et al. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy—the Austrian experience. *Seizure* (2010) 19:404–8. doi: 10.1016/j.seizure.2010.06.006
29. Boison D. New insights into the mechanisms of the ketogenic diet. *Curr Opin Neurol*. (2017) 30:187–92. doi: 10.1097/WCO.0000000000000432
30. El YM, Ledent C, Parmentier M, Costentin J, Vaugeois JM. Evidence for the involvement of the adenosine A(2A) receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine. *Neuropharmacology* (2008) 55:35–40. doi: 10.1016/j.neuropharm.2008.04.007
31. Curia G, Longo D, Biagini G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. *J Neurosci Methods* (2008) 172:143–7. doi: 10.1016/j.jneumeth.2008.04.019
32. Boison D, Steinhauser C. Epilepsy and astrocyte energy metabolism. *GLIA* (2018) 66:1235–43. doi: 10.1002/glia.23247
33. Simeone KA, Matthews SA, Rho JM, Simeone TA. Ketogenic diet treatment increases longevity in Kcna1-null mice, a model of sudden unexpected death in epilepsy. *Epilepsia* (2016) 57:e178–82. doi: 10.1111/epi.13444
34. Ryvlin P, Nashef L, Lhatoo SD, Bateman LM, Bird J, Bleasel A, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. *Lancet Neurol*. (2013) 12:966–77. doi: 10.1016/S1474-4422(13)70214-X
35. Simeone TA, Samson KK, Matthews SA, Simeone KA. *In vivo* ketogenic diet treatment attenuates pathological sharp waves and high frequency oscillations in *in vitro* hippocampal slices from epileptic Kv 1.1alpha knockout mice. *Epilepsia* (2014) 55: e44–9. doi: 10.1111/epi.12603
36. Kim DY, Simeone KA, Simeone TA, Pandya JD, Wilke JC, Ahn Y, et al. Ketone bodies mediate antiseizure effects through mitochondrial permeability transition. *Ann Neurol*. (2015) 78:77–87. doi: 10.1002/ana.24424
37. Simeone KA, Hallgren J, Bockman CS, Aggarwal A, Kansal V, Netzel L, et al. Respiratory dysfunction progresses with age in Kcna1-null mice, a model of sudden unexpected death in epilepsy. *Epilepsia* (2018) 59:345–57. doi: 10.1111/epi.13971
38. Moore BM, Jerry JC, Tatalovic M, Kaufman ES, Kline DD, Kunze DL. The Kv1.1 null mouse, a model of sudden unexpected death in epilepsy (SUDEP). *Epilepsia* (2014) 55:1808–16. doi: 10.1111/epi.12793
39. Pitkanen A, McIntosh TK. Animal models of post-traumatic epilepsy. *J Neurotrauma*. (2006) 23:241–61. doi: 10.1089/neu.2006.23.241
40. Schwartzkroin PA, Wenzel HJ, Lyeth BG, Poon CC, Delance A, Van KC, et al. Does ketogenic diet alter seizure sensitivity and cell loss following fluid percussion injury? *Epilepsy Res*. (2010) 92:74–84. doi: 10.1016/j.eplepsyres.2010.08.009
41. Linard B, Ferrandon A, Koning E, Nehlig A, Raffo E. Ketogenic diet exhibits neuroprotective effects in hippocampus but fails to prevent epileptogenesis in the lithium-pilocarpine model of mesial temporal lobe epilepsy in adult rats. *Epilepsia* (2010) 51:1829–36. doi: 10.1111/j.1528-1167.2010.02667.x
42. Martin-McGill KJ, Jackson CF, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. *Cochrane Database Syst Rev*. (2018) 11:D1903. doi: 10.1002/14651858.CD001903.pub4
43. Lambrechts D, de Kinderen R, Vles J, de Louw A, Aldenkamp AP, Majoie H. A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. *ACTA Neurol Scand*. (2018) 137:152–4. doi: 10.1111/ane.12802
44. El-Rashidy OF, Nassar MF, Abdel-Hamid IA, Shatla RH, Abdel-Hamid MH, Gabr SS, et al. Modified Atkins diet vs classic ketogenic formula in intractable epilepsy. *ACTA Neurol Scand*. (2013) 128:402–8. doi: 10.1111/ane.12137
45. Kim JA, Yoon JR, Lee EJ, Lee JS, Kim JT, Kim HD, et al. Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy. *Epilepsia* (2016) 57:51–8. doi: 10.1111/epi.13256
46. Raju KN, Gulati S, Kabra M, Agarwala A, Sharma S, Pandey RM, et al. Efficacy of 4:1 (classic) versus 2.5:1 ketogenic ratio diets in refractory epilepsy in young children: a randomized open labeled study. *Epilepsy Res*. (2011) 96:96–100. doi: 10.1016/j.eplepsyres.2011.05.005
47. Luan G, Gao Q, Zhai F, Zhou J, Liu C, Chen Y, et al. Adenosine kinase expression in cortical dysplasia with balloon cells: analysis of developmental lineage of cell types. *J Neuropathol Exp Neurol*. (2015) 74:132–47. doi: 10.1097/NEN.0000000000000156
48. Li T, Ren G, Lusardi T, Wilz A, Lan JQ, Iwasato T, et al. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. *J Clin Invest*. (2008) 118:571–82. doi: 10.1172/JCI33737
49. Li T, Steinbeck JA, Lusardi T, Koch P, Lan JQ, Wilz A, et al. Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. *Brain* (2007) 130:1276–88. doi: 10.1093/brain/awm057
50. Li T, Lytle N, Lan JQ, Sandau US, Boison D. Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: a first step in epileptogenesis? *GLIA* (2012) 60:83–95. doi: 10.1002/glia.21250
51. Williams-Karnesky RL, Sandau US, Lusardi TA, Lytle NK, Farrell JM, Pritchard EM, et al. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. *J Clin Invest*. (2013) 123:3552–63. doi: 10.1172/JCI65636
52. Luan G, Wang X, Gao Q, Guan Y, Wang J, Deng J, et al. Upregulation of neuronal adenosine A1 receptor in human rasmussen encephalitis. *J Neuropathol Exp Neurol*. (2017) 76:720–31. doi: 10.1093/jnen/nlx053
53. Luan G, Gao Q, Guan Y, Zhai F, Zhou J, Liu C, et al. Upregulation of adenosine kinase in Rasmussen encephalitis. *J Neuropathol Exp Neurol*. (2013) 72:1000–8. doi: 10.1097/01.jnen.0000435369.39388.5c
54. Borea PA, Gessi S, Merighi S, Varani K. Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? *Trends Pharmacol Sci*. (2016) 37:419–34. doi: 10.1016/j.tips.2016.02.006
55. Li T, Quan LJ, Fredholm BB, Simon RP, Boison D. Adenosine dysfunction in astroglia: cause for seizure generation? *Neuron Glia Biol*. (2007) 3:353–66. doi: 10.1017/S1740925X0800015X
56. Li T, Ren G, Kaplan DL, Boison D. Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis. *Epilepsy Res*. (2009) 84:238–41. doi: 10.1016/j.eplepsyres.2009.01.002
57. Wilz A, Pritchard EM, Li T, Lan JQ, Kaplan DL, Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. *Biomaterials* (2008) 29:3609–16. doi: 10.1016/j.biomaterials.2008.05.010
58. Reppert SM, Weaver DR, Stehle JH, Rivkees SA. Molecular cloning and characterization of a rat A1-adenosine receptor that is widely

- expressed in brain and spinal cord. *Mol Endocrinol.* (1991) 5:1037–48. doi: 10.1210/mend-5-8-1037
59. Wardas J. Neuroprotective role of adenosine in the CNS. *Pol J Pharmacol.* (2002) 54:313–26. Available online at: [http://www.ifpan.krakow.pl/pjp/pdf/2002/4\\_313.pdf](http://www.ifpan.krakow.pl/pjp/pdf/2002/4_313.pdf)
  60. Boison D. Adenosinergic signaling in epilepsy. *Neuropharmacology* (2016) 104:131–9. doi: 10.1016/j.neuropharm.2015.08.046
  61. Kobow K, Blumcke I. The emerging role of DNA methylation in epileptogenesis. *Epilepsia* (2012) 53:11–20. doi: 10.1111/epi.12031
  62. Younus I, Reddy DS. Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy. *Pharmacol Ther.* (2017) 177:108–22. doi: 10.1016/j.pharmthera.2017.03.002
  63. Bao Y, Chen X, Wang L, Zhou J, Fu X, Wang X, et al. RASgrf1, a Potential Methylatic Mediator of Anti-epileptogenesis? *Neurochem Res.* (2018) 43:2000–7. doi: 10.1007/s11064-018-2621-9
  64. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. *J Chronic Dis.* (1970) 23:455–68. doi: 10.1016/0021-9681(70)90054-8
  65. Novy J, Bell GS, Peacock JL, Sisodiya SM, Sander JW. Epilepsy as a systemic condition: link with somatic comorbidities. *Acta Neurol Scand.* (2017) 136:352–9. doi: 10.1111/ane.12779
  66. Li T. Epilepsy and associated comorbidities. *Neuropsychiatry(Lond)* (2017) 1:1–3. doi: 10.4172/Neuropsychiatry.1000e101
  67. Stafstrom CE. Issues in clinical epileptology: a view from the bench. festschrift in honor of philip a. schwartzkroin, PhD. *Epilepsy Curr.* (2013) 13:291–6. doi: 10.5698/1535-7597-13.6.291
  68. Gaitatzis A, Carroll K, Majeed A, WSJ. The epidemiology of the comorbidity of epilepsy in the general population. *Epilepsia* (2004) 45:1613–22. doi: 10.1111/j.0013-9580.2004.17504.x
  69. Mutlu A. Association between epilepsy and headache. *Neurol Sci.* (2018) 39:2129–34. doi: 10.1007/s10072-018-3558-0
  70. Latreille V, St LE, Pavlova M. Co-morbid sleep disorders and epilepsy: a narrative review and case examples. *Epilepsy Res.* (2018) 145:185–97. doi: 10.1016/j.eplepsyres.2018.07.005
  71. Ottman R, Lipton RB, Ettinger AB, Cramer JA, Reed ML, Morrison A, et al. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. *Epilepsia* (2011) 52:308–15. doi: 10.1111/j.1528-1167.2010.02927.x
  72. Kumar U, Medel-Matus JS, Redwine HM, Shin D, Hensler JG, Sankar R, et al. Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy. *Epilepsia* (2016) 57:506–15. doi: 10.1111/epi.13321
  73. Medel-Matus JS, Shin D, Sankar R, Mazarati A. Kindling epileptogenesis and panic-like behavior: their bidirectional connection and contribution to epilepsy-associated depression. *Epilepsy Behav.* (2017) 77:33–8. doi: 10.1016/j.yebeh.2017.10.001
  74. Aguilar BL, Malkova L, N'Gouemo P, Forcelli PA. Genetically epilepsy-prone rats display anxiety-like behaviors and neuropsychiatric comorbidities of epilepsy. *Front Neurol.* (2018) 9:476. doi: 10.3389/fneur.2018.00476
  75. Medel-Matus JS, Shin D, Sankar R, Mazarati A. Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy. *Exp Neurol.* (2017) 289:64–72. doi: 10.1016/j.expneurol.2016.12.008
  76. Wilson SJ, Baxendale S. Reprint of: The new approach to classification: rethinking cognition and behavior in epilepsy. *Epilepsy Behav.* (2016) 64:300–3. doi: 10.1016/j.yebeh.2016.11.024
  77. Hermann BP, Dabbs K, Becker T, Jones JE, Myers YGA, Wendt G, et al. Brain development in children with new onset epilepsy: a prospective controlled cohort investigation. *Epilepsia* (2010) 51:2038–46. doi: 10.1111/j.1528-1167.2010.02563.x
  78. Hermann B, Jones J, Sheth R, Dabbs K, Allen CA, Sheth R, Fine J, et al. The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. *Brain* (2007) 130:3135–48. doi: 10.1093/brain/awm227
  79. Hermann B, Jones J, Sheth R, Dow C, Koehn M, Seidenberg M. Children with new-onset epilepsy: neuropsychological status and brain structure. *Brain* (2006) 129:2609–19. doi: 10.1093/brain/awl196
  80. Salpekar JA, Mula M. Common psychiatric comorbidities in epilepsy: how big of a problem is it? *Epilepsy Behav.* (2018). doi: 10.1016/j.yebeh.2018.07.023
  81. Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. *Nat Rev Neurol.* (2016) 12:106–16. doi: 10.1038/nrneurol.2015.243
  82. Garcia-Penas JJ. [Epilepsy, cognition and ketogenic diet]. *Rev Neurol.* (2018) 66:S71–5. Available online at: <https://www.neurologia.com/articulo/2017529>
  83. Zhao M, Huang X, Cheng X, Lin X, Zhao T, Wu L, et al. Ketogenic diet improves the spatial memory impairment caused by exposure to hypobaric hypoxia through increased acetylation of histones in rats. *PLoS ONE* (2017) 12:e174477. doi: 10.1371/journal.pone.0174477
  84. Garcia-Penas JJ. Epilepsy, cognition and ketogenic diet. *Rev Neurol.* (2018) 66: S71–5.
  85. Terrone G, Pauletti A, Salamone A, Rizzi M, Villa BR, Porcu L, et al. Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. *Epilepsia* (2018) 59:79–91. doi: 10.1111/epi.13950
  86. Ni H, Zhao DJ, Tian T. Ketogenic diet change cPLA2/clusterin and autophagy related gene expression and correlate with cognitive deficits and hippocampal MFs sprouting following neonatal seizures. *Epilepsy Res.* (2016) 120:13–8. doi: 10.1016/j.eplepsyres.2015.11.021
  87. Bostock EC, Kirkby KC, Taylor BV. The current status of the ketogenic diet in psychiatry. *Front Psychiatry* (2017) 8:43. doi: 10.3389/fpsy.2017.00043
  88. Brietzke E, Mansur RB, Subramaniapillai M, Balanza-Martinez V, Vinberg M, Gonzalez-Pinto A, et al. Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. *Neurosci Biobehav Rev.* (2018) 94:11–6. doi: 10.1016/j.neubiorev.2018.07.020
  89. Li T, Gao Q, Luan G. Adenosine dysfunction in Rasmussen's encephalitis. *Neuropsychiatry (London)* (2016) 6:280–5. doi: 10.4172/neuropsychiatry.1000150
  90. Boison D, Aronica E. Comorbidities in neurology: is adenosine the common link? *Neuropharmacology* (2015) 97:18–34. doi: 10.1016/j.neuropharm.2015.04.031
  91. Matos M, Shen HY, Augusto E, Wang Y, Wei CJ, Wang YT, et al. Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia. *Biol Psychiatry* (2015) 78:763–74. doi: 10.1016/j.biopsych.2015.02.026
  92. Shen HY, Singer P, Lytle N, Wei CJ, Lan JQ, Williams-Karnesky RL, et al. Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia. *J Clin Invest.* (2012) 122:2567–77. doi: 10.1172/JCI62378
  93. Friedman D, Spruill TM, Liu H, Tatsuoka C, Stoll S, Jobst BC, et al. Depressive symptoms and suicidality among individuals with epilepsy enrolled in self-management studies: results from the US Centers for Disease Control and Prevention Managing Epilepsy Well (MEW) Network. *Epilepsy Behav.* (2018) 87:235–40. doi: 10.1016/j.yebeh.2018.06.024
  94. Hines DJ, Schmitt LI, Hines RM, Moss SJ, Haydon PG. Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling. *Transl Psychiatry* (2013) 3:e212. doi: 10.1038/tp.2012.136
  95. De Berardis D, Marini S, Serroni N, Rapini G, Iasevoli F, Valchera A, et al. S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. *ScientificWorldJournal* (2013) 2013:204649. doi: 10.1155/2013/204649
  96. Georgoudis G, Felah B, Nikolaidis PT, Papandreou M, Mitsiokappa E, Mavrogenis AE, et al. The effect of physiotherapy and acupuncture on psychocognitive, somatic, quality of life, and disability characteristics in TTH patients. *J Pain Res.* (2018) 11:2527–35. doi: 10.2147/JPR.S178110
  97. Sallach K, Leonhardt M. Acupuncture for treatment of depressive disorders in pain diseases. *Nervenarzt* (2018) 89:986–93. doi: 10.1007/s00115-018-0576-3
  98. Drobisz D, Damborska A. Deep brain stimulation targets for treating depression. *Behav Brain Res.* (2019) 359:266–73. doi: 10.1016/j.bbr.2018.11.004
  99. Bekar L, Libionka W, Tian GF, Xu Q, Torres A, Wang X, et al. Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor. *Nat Med.* (2008) 14:75–80. doi: 10.1038/nm1693

100. Miranda MF, Hamani C, de Almeida AC, Amorim BO, Macedo CE, Fernandes MJ, et al. Role of adenosine in the antiepileptic effects of deep brain stimulation. *Front Cell Neurosci.* (2014) 8:312. doi: 10.3389/fncel.2014.00312
101. Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. *Nat Neurosci.* (2010) 13:883–8. doi: 10.1038/nn.2562
102. Blustein T, Haydon PG. The Importance of astrocyte-derived purines in the modulation of sleep. *GLIA* (2013) 61:129–39. doi: 10.1002/glia.22422
103. Halassa MM, Florian C, Fellin T, Munoz JR, Lee SY, Abel T, et al. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. *Neuron* (2009) 61:213–9. doi: 10.1016/j.neuron.2008.11.024
104. Benington JH, Kodali SK, Heller HC. Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. *Brain Res.* (1995) 692:79–85. doi: 10.1016/0006-8993(95)00590-M
105. Virus RM, Ticho S, Pilditch M, Radulovacki M. A comparison of the effects of caffeine, 8-cyclopentyltheophylline, and alloxazine on sleep in rats. possible roles of central nervous system adenosine receptors. *Neuropsychopharmacol* (1990) 3:243–9.
106. Satoh S, Matsumura H, Hayaishi O. Involvement of adenosine A2A receptor in sleep promotion. *Eur J Pharmacol.* (1998) 351:155–62. doi: 10.1016/S0014-2999(98)00302-1
107. Scammell TE, Gerashchenko DY, Mochizuki T, McCarthy MT, Estabrooke IV, Sears CA, et al. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. *Neuroscience* (2001) 107:653–63. doi: 10.1016/S0306-4522(01)00383-9
108. Urade Y, Eguchi N, Qu WM, Sakata M, Huang ZL, Chen JF, et al. Sleep regulation in adenosine A2A receptor-deficient mice. *Neurology* (2003) 61:S94–6. doi: 10.1212/01.WNL.0000095222.41066.5E
109. Lazarus M, Shen HY, Cherasse Y, Qu WM, Huang ZL, Bass CE, et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. *J Neurosci.* (2011) 31:10067–75. doi: 10.1523/JNEUROSCI.6730-10.2011
110. Warren TJ, Simeone TA, Smith DD, Grove R, Adamec J, Samson KK, et al. Adenosine has two faces: regionally dichotomous adenosine tone in a model of epilepsy with comorbid sleep disorders. *Neurobiol Dis.* (2018) 114:45–2. doi: 10.1016/j.nbd.2018.01.017

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Chen, He, Luan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.